冷泉港亞洲2013會(huì)議：腫瘤免疫及免疫療法
Tumor Immunology and Immunotherapy
腫瘤免疫及免疫療法
2013年10月28 – 11月1日 | 蘇州. 獨(dú)墅湖會(huì)議酒店
http://www.csh-asia.org/13Immune.html
科學(xué)組委會(huì)成員:
Xuetao Cao, Chinese Academy of Medical Sciences, China
Xin-Yuan Fu, National University of Singapore, Singapore
Olivera Finn, University of Pittsburgh School of Medicine, USA
Cornelius Melief, Leiden University Medical Center, The Netherlands
會(huì)議主題：
1. Cancer vaccines
2. Antibody therapy
3. Adoptive T cell therapy
4. Combination of immunotherapy with other therapies
5. Cancer, inflammation and immunosuppression
6. Immune escape of cancer
7. Aging, immunity and cancer
8. Oncogenic viruses, immunity and immunotherapy
主題演講嘉賓:
David Baltimore, California Institute of Technology, USA
Engineering Immunologic Protection and Therapy
Xiaodong Wang, National Institute of Biological Sciences, China
TNFalpha and TLR3/4 induced necrosis pathway
特邀演講嘉賓:
Jean Pierre Abastado, Singapore Immunology Network, Singapore
Cancer cells hijack immune cells for dissemination and metastasis.
Jannie Borst, The Netherlands Cancer Institute, The Netherlands
Mechanistic insights in T-cell costimulation by the CD27/CD70 pathway encourage application in cancer immunotherapy
Jay Berzofsky, National Cancer Institute, USA
Cancer Vaccines: Basic strategies and clinical translation
Vincenzo Bronte, University of Verona, Italy
Molecular and metabolic control of adaptive immunity by tumor-induced myelopoiesis
Xuetao Cao, Chinese Academy of Medical Sciences, China
New cell subsets in tumor immune escape and metastasis
Yuan Chang, University of Pittsburgh Cancer Institute, USA
Merkel cell polyomavirus: a model in tumorigenesis and immunity
Lieping Chen, Yale School of Medicine, USA
Inhibiting co-inhibitors for immunotherapy of cancer
Olivera Finn, University of Pittsburgh School of Medicine, USA
Disease associated antigens as targets for cancer immunosurvellance and candidates for prophylactic cancer vaccines
Xin-Yuan Fu, National University of Singapore, Singapore
An Inducible Cancer Metastatic Niche Mediated by Endothelial STAT3
Yang-Xin Fu, The University of Chicago, USA
Changing tumor microenvironment by local ablative radiation and modified antibody for better immunotherapy
Yukai He, Georgia Regents University Cancer Center, USA
Engineering epitope-optimized AFP-based gene vaccines to prevent autochthonous hepatocellular carcinoma
Erica Jensen Jarolim, Medical University Vienna, Austria
Comparative oncology: Development of xenogenic vaccines and recombinant antibodies for dog mammary cancer patients.
Dieter Kabelitz, University of Kiel, Germany
Towards improving immunotherapeutic strategies with human gamma/delta T-cells
Yutaka Kawakami, Keio University School of Medicine, Japan
Different tumor immunoenvironments among patients and their modification by molecular targeted therapy
Binfeng Lu, University of Pittsburgh School of Medicine, USA
Danger signal IL-33 and antitumor Immunity
Ignacio Melero, University of Navarra, Spain
unfolding CD137-based cancer immunotherapy
Cornelius Melief, Leiden University Medical Center, The Netherlands
TLR-ligand peptide conjugates for superior therapeutic vaccination against immunogenic cancers
Ira Mellman, Genentech, USA
Oncology meets immunology: targeting PD-L1 in combination
Andrew Mellor, Georgia Regents University, USA
A Tale with a STING: Pivotal pathways that control immune responses to DNA
Graham Pawelec, University of Tuebingen Center for Medical Research, Germany
Immunosenescence and cancer
Zhihai Qin ,Chinese Academy of Sciences, China
S100A4(FSP-1)promotes liver fibrosis and hepatocellular carcinoma
Michel Sadelain, Memorial Sloan-Kettering Cancer Center, USA
Targeting tumors with genetically enhanced T lymphocytes
Mark Smyth, Queensland Institute of Medical Research in Brisbane, Australia
Receptor ligand interactions that regulate tumor growth and metastases
Cassian Yee, UT MD Anderson Cancer Center, USA
Adoptive T Cell Therapy of Cancer: Age of Renaissance
Hua Yu, City of Hope Duarte, USA
Pathways to Targeting STAT3: Transition into the Clinic
Rong-Fu Wang, The Methodist Hospital Research Institute Houston, USA
Innate signaling and antigen-specific cancer immunotherapy
Limin Zheng, Sun Yat-sen University, China
Macrophage Plasticity in Distinct Microenvironments of Human Tumors
Weiping Zou, University of Michigan Medical School, USA
Immune elements shape cancer stemness
|
|
聯(lián)系方式： Cold Spring Harbor Asia No.299 Qiyue Road, SIP/ Suzhou, Jiangsu Province, China Tel: +86-512-62729029 Fax: +86-512-62729028 Email: mikeji@cshl.edu Website: www.csh-asia.org |
相關(guān)鏈接： 2013年冷泉港亞洲（CSH Asia）會(huì)議搶先預(yù)覽！
- 相約成都：博格隆邀您參加2025未來XDC新藥大會(huì)
- 艾貝泰誠(chéng)將攜生物反應(yīng)器等參加中國(guó)生物制品大會(huì)
- 首屆中樞神經(jīng)創(chuàng)新藥物研發(fā)與轉(zhuǎn)化醫(yī)學(xué)峰會(huì)通知
- AIDC2025自免藥物創(chuàng)新開發(fā)及應(yīng)用大會(huì)通知
- 賽恩科儀邀您參加2025第九屆全國(guó)磁性材料與器件大會(huì)
- BSI邀您參加2025年第六屆全國(guó)糖科學(xué)青年科技論壇
- ChinaBio®2025生物醫(yī)藥產(chǎn)業(yè)國(guó)際合作大會(huì)倒計(jì)時(shí)2周
- 第47屆中原醫(yī)療器械(2025年秋季)展覽會(huì)通知
- CIS-Asia2025第十八屆百世化學(xué)制藥大會(huì)通知
- EVIDENT煥新亮相細(xì)胞年會(huì)以"奧偉登"之名加速本土化
- FTMSI 2025第23屆現(xiàn)代科學(xué)儀器前沿技術(shù)研討會(huì)通知
- 2025 細(xì)胞產(chǎn)業(yè)大會(huì)（深圳）通知
- 2025生物藥創(chuàng)新開發(fā)峰會(huì)（深圳）通知
- 普瑞邦與您相約CBIFS2025 第十七屆食品安全技術(shù)論壇
- 新諾攜壓片機(jī)等成功參展北京科學(xué)儀器展CISILE 2025
- 細(xì)胞檢測(cè)試劑盒免費(fèi)送，反饋即享100%京東卡好禮！
- 2025動(dòng)物生物育種與繁殖技術(shù)學(xué)術(shù)交流研討會(huì)通知
- 開年上新：尚恩生物細(xì)胞轉(zhuǎn)染服務(wù)正式上線啦!
- 尚恩生物開年大促銷，福利疊滿解鎖新學(xué)期！
- 尚恩生物年終大促—4款細(xì)胞系套餐送500ml完全培養(yǎng)基
- 尚恩生物雙11促銷：任意細(xì)胞系+配套完培下單立減100
- 賽業(yè)今晚直播：點(diǎn)突變細(xì)胞株構(gòu)建策略及其研究應(yīng)用
- 賽業(yè)講座：兩步灌流法提取原代鼠肝臟Kupffer細(xì)胞
- 賽業(yè)生物課程預(yù)告：基因編輯細(xì)胞技術(shù)及其研究應(yīng)用
- 賽業(yè)生物明日開播：CAR-T細(xì)胞的結(jié)構(gòu)設(shè)計(jì)策略
- 尚恩生物細(xì)胞特價(jià)—30株細(xì)胞系限時(shí)890元/株
- 尚恩生物——胎牛血清、原代細(xì)胞福利大放送
- 尚恩生物6月促銷：1380元超值寵粉細(xì)胞套裝限時(shí)購(gòu)
- 科德角國(guó)際正式成為ATCC菌株產(chǎn)品中國(guó)授權(quán)合作商
- 賽業(yè)生物課程預(yù)告：星形膠質(zhì)細(xì)胞培養(yǎng)和應(yīng)用
Copyright(C) 1998-2025 生物器材網(wǎng) 電話：021-64166852;13621656896 E-mail：info@bio-equip.com